A new study examines how cost, side effects, and other factors influence whether people stop GLP-1s, while Noom cuts staff to ...

Nearly 2 in 3 people without diabetes quit popular weight loss drugs such as Ozempic or Victoza within one year, according to ...

Discover how modern diabetes medications offer cardiovascular benefits, transforming diabetes care and improving outcomes worldwide.

Semaglutide's role extends beyond diabetes, aiding weight loss and offering cardiovascular protection, with ongoing research ...

New research found that over half of people with type 2 diabetes in the Americas may be deficient in essential nutrients, ...

WVU Medicine is playing a lead role in a national clinical study of a minimally invasive surgical procedure for people who've ...

New GLP-1RA weight loss drugs like Like Ozempic and Wegovy have become extremely popular in recent months but researchers ...

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...

The results of this comparative effectiveness research study suggest that sodium-glucose cotransporter-2 inhibitors  and glucagon-like peptide-1 receptor agonists (GLP-1RAs) were associated with a ...

The results were consistent with the preliminary results Eli Lilly shared in January, which disappointed investors.

Subscribe here to receive future editions. Most people quit a highly popular class of weight loss and diabetes drugs called GLP-1s within a year of starting them, several studies have shown.